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Abstract
Background: Young women receiving family planning services are at risk for both unintended
pregnancy and herpes simplex virus type 2 (HSV-2) infection.
Methods: We performed a secondary analysis using data from a previously published randomized
controlled trial evaluating access to emergency contraception on reproductive health outcomes.
Women aged 15 to 24 years were recruited from two Planned Parenthood clinics and two
community health clinics in San Francisco. Demographic information and sexual history were
obtained by interview. HSV-2 seropositivity was determined by fingerstick blood test. New
pregnancies were measured by self-report, urine testing and medical chart review. Subjects were
evaluated for incident HSV-2 infection and pregnancy at a 6-month follow-up appointment. Women
who were pregnant or intending to become pregnant at enrolment were excluded.
Results: At enrolment 2,104 women were screened for HSV-2 and 170 (8.1%) were seropositive.
Eighty-seven percent of initially seronegative women completed the study (n = 1,672) and 73 (4.4%)
became HSV-2 seropositive. HSV-2 seroincidence was 7.8 cases per 100 person-years. One
hundred and seventeen women (7%) became pregnant and 7 (6%) of these had a seroincident HSV-
2 infection during the study. After adjustment for confounders, predictors of incident HSV-2
infection were African American race and having multiple partners in the last six months. Condom
use at last sexual encounter was protective.
Conclusion: HSV-2 seroincidence and the unintended pregnancy rate in young women were high.
Providers who counsel women on contraceptive services and sexually transmitted infection
prevention could play an expanded role in counselling women about HSV-2 prevention given the
potential sequelae in pregnancy. The potential benefit of targeted screening and future vaccination
against HSV-2 needs to be assessed in this population.
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Background
Sexually active young women in the United States are
exposed to herpes simplex virus type 2 (HSV-2) with high
frequency. There currently is no cure for HSV-2 and clini-
cal manifestations may be controlled with periodic or
long-term suppressive medical therapy. Few (10%)
infected individuals report symptomatic disease, typically
consisting of painful genital sores, although forward
transmission is possible with no reported symptoms. In
addition, HSV-2 seropositivity is a known risk factor for
human immunodeficiency virus (HIV) acquisition [1,2].
HSV-2 infections are known to have especially serious
clinical sequelae in neonates. In general, women with pre-
pregnancy HSV-2 seropositivity have a reduced risk of
neonatal transmission, attributed to the passage of trans-
placental antibodies to the foetus, but women with a
recurrent herpes episode at delivery generally undergo
caesarean section to prevent transmission to the neonate
[3-5]. Pre-pregnancy seronegative women with an inci-
dent herpes infection are also at high risk for HSV-2 trans-
mission and neonatal complications [6].
National Health and Nutrition Examination Survey
(NHANES) surveillance data collected from 1999 through
2004 found an HSV-2 seroprevalence of 23.1% in US
females aged 14 to 49 years [7]. While overall HSV-2 sero-
prevalence has declined in recent years and is estimated to
be only 2.3% in females aged 14 to 19 years, it increases
to 15.6% in females aged 20 to 29 years indicating high
acquisition rates during this age transition [7].
In San Francisco, young women under age 25 account for
the highest heterosexually transmitted incidence rates of
reportable sexually transmitted diseases (STD), such as
Chlamydia trachomatis (CT) and Neisseria gonorrhea (GC)
[8]. This population is at high risk of HSV-2 acquisition,
although new infections are not reportable making inci-
dence measurements challenging. These young women
are most likely also at high risk for unintended pregnancy.
In national data from 2001, high risk of unintended preg-
nancy was associated with age 18 to 24 years, low-income,
minority racial status, and failure to complete high school
[9]. The risk of HSV-2 infection in women with high unin-
tended pregnancy rates presents a particularly concerning
situation.
With this study we sought to determine predictors of inci-
dent HSV-2 infection and concurrent unintended preg-
nancy in a racially diverse cohort of young, sexually active
urban women seeking family planning services.
Methods
Between July 2001 and June 2003 women between the
ages of 15 and 24 years were recruited from four clinics
serving adolescents and young adults with family plan-
ning needs in San Francisco City and County, California.
The resulting cohort was assembled as part of a rand-
omized controlled trial (RCT) evaluating access to emer-
gency contraception on reproductive health outcomes. A
complete description of the methods has been published
elsewhere [10]. In brief, the clinics included two Planned
Parenthood clinics, a college health centre providing pri-
mary care services, and a community clinic for young
adults. Women attending scheduled appointments or
unscheduled drop-in visits as well as those women
accompanying them were referred to study personnel.
English and Spanish speaking women were then screened
for eligibility to participate. Women in the targeted age
range who reported sexual intercourse in the previous six
months were eligible for the study. Pregnant women,
women refusing a pregnancy test, women wishing to
become pregnant in the next six months and women
using low compliance contraceptive methods – injecta-
bles, intrauterine devices (IUDs), or implants – were
excluded. Women who reported unprotected intercourse
in the previous three days were also excluded. These exclu-
sions were necessary for the purposes of the RCT emer-
gency contraception study. Reason for study exclusion
only was collected on women ineligible for study partici-
pation.
Study personnel interviewed all participants at enrolment
using a standardized questionnaire collecting demo-
graphic information, sexual history and risk behaviours.
All information was self-reported and not verified by
review of medical records.
Participants were then tested for HSV-2 antibodies by
POCKit HSV-2 rapid point-of-care test (Diagnology Inc,
Belfast, Northern Ireland) on fingerstick whole blood
samples. POCKit tests were donated by the manufacturer
for study use and the test was considered less invasive
than venipuncture and thus more acceptable for study
participants. This test is now available as "biokitHSV-2
Rapid Test" from Biokit USA, Lexington, MA or as "Sure-
Vue-HSV-2" Rapid Test from Fisher HealthCare, Houston,
TX. Premarket evaluation of this test against culture-docu-
mented and Western blot confirmed HSV-2 negative (n =
50) and HSV-2 positive (n = 253) showed POCKit HSV-2
test sensitivity was 96% and specificity was 98% [11]. Sen-
sitivity for HSV-2 was not affected by the presence of HSV-
1 antibodies. In this premarket evaluation, discordant
specimens were further examined by repeat Western blot
testing. POCKit falsely identified one specimen as positive
for HSV-2 (unknown reason for false positive) and falsely
identified eight specimens as negative for HSV-2 (due to
low titre levels in the specimens).BMC Infectious Diseases 2007, 7:113 http://www.biomedcentral.com/1471-2334/7/113
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Participants also submitted a urine specimen for preg-
nancy testing (Clearview One Step, Unipath Diagnostics,
Waltham, MA, or equivalent) and Chlamydia trachomatis
(CT) nucleic acid amplification testing (BD ProbeTec, Bec-
ton Dickinson & Co, Sparks, MD).
Each participant had a follow-up interview approximately
six months later at either the enrolling clinic or at her
home. Interviews were conducted by telephone when nec-
essary; however, women who had telephone follow-up
were unavailable for repeat HSV-2 and pregnancy testing.
This second interview asked participants about any new
STI diagnosis, pregnancy or change in risk behaviours
since enrolment using a standardized questionnaire.
Repeat HSV-2 and pregnancy testing, as well as a medical
chart review for interim HSV-2 infection or pregnancy,
were also performed at the 6-month follow-up, when pos-
sible.
All subjects were compensated with $10 at enrolment and
$20 at follow-up. All women who tested positive for CT at
enrolment were referred to a clinic for treatment and part-
ner management per clinic protocol. Women testing pos-
itive for HSV-2 antibodies were only informed and
counselled on HSV-2 antibody results if the individual
participant so requested, as routine HSV-2 screening of
patients was not the standard of care at participating clin-
ics. Women with positive rapid HSV-2 antibody results
were told they could seek confirmatory testing at their dis-
cretion, however, confirmatory test results were not
recorded as a part of this study. Information on number
and characteristics of participants requesting HSV-2
results was not recorded. Pregnancy outcomes of partici-
pants with HSV-2 infection were also not recorded, as
study participation was complete at six months.
The primary outcome assessed was HSV-2 seroconversion
during the study period. The secondary outcome was inci-
dent pregnancy among those with follow-up testing for
HSV-2.
Statistical Analysis
Approximately twenty baseline demographic, historical,
biological and behavioural measures that, based on rele-
vant literature, might be associated with HSV-2 were indi-
vidually evaluated for significance for both prevalent and
incident HSV-2 infection. Dichotomous variables were
evaluated for significance with the Chi-squared test; mul-
tilevel categorical variables were analyzed using a General
Chi-squared test. Odds ratios (OR) and 95% confidence
intervals (CI) were generated with logistic regression for
incident HSV-2 infection among select variables. Factors
previously reported to be predictors of HSV-2 as well as
factors approaching significance (p ≤ 0.1) in the bivariate
logistic regression analysis were included in an initial
multivariable model. The final model was constructed
using a combination of automatic and manual reverse
stepwise selection. Frequency tables and statistical com-
putations were performed using Stata 9.1 (Stata Corpora-
tion, College Station, TX) and SAS 9.1 (SAS Institute Inc.,
Cary, NC). Incidence densities were calculated by dividing
incident events by the total time between enrolment and
either follow-up appointment or time of incident event
for all participants. Incident HSV-2 infection or pregnancy
was assumed to have occurred mid-way through the fol-
low-up interval. Ninety-five percent exact confidence lim-
its for incidence density estimates were calculated using
SAS.
Informed consent for participation in the study was
obtained from all women. The University of California
San Francisco (UCSF) Committee on Human Research
and Planned Parenthood approved the study, including
all methods, questionnaires and consent documents.
Results
In total, 4,361 women from the four clinics were screened
for study eligibility. Fifty-one percent did not meet RCT
emergency contraception study eligibility requirements
with 15% reporting unprotected intercourse in the previ-
ous 3 days, 10% using injectable contraceptives, 9% not
receiving a pregnancy test, 7% not sexually active in last 6
months, 2% pregnant, and 8% ineligible for other rea-
sons. Of the 2,130 women eligible for the emergency con-
traception study, 13 refused participation, 13 did not have
HSV-2 testing at baseline, and 2,104 were enrolled in the
HSV-2 study. At enrolment, 170 women (8.1%) tested
positive for HSV-2 serum antibodies. HSV-2 seropositivity
by selected demographic and behavioural characteristics
at enrolment is presented in Table 1.
Of the 1,934 women who were HSV-2 seronegative at
enrolment, 1,672 (86.5%) had repeat HSV-2 testing per-
formed at six months. The remaining 262 women were
lost to follow-up or did not have HSV-2 lab results availa-
ble from follow-up testing. The mean time to follow-up
was 6.9 +/- 1.3 months. Seventy-three (4.4%) of those
women tested at follow-up were found to be seropositive
for HSV-2 antibodies, which is equivalent to an incidence
rate of 7.8 (3.3 – 15.5) cases per 100 person-years.
Of the 1,672 women with HSV-2 laboratory follow-up,
117 (7.0%) became pregnant during the study, resulting
in an incidence rate of 12.7 (6.7 – 21.9) unintended preg-
nancies per 100 person-years. Seven women (0.4%) had
both incident HSV-2 infection and pregnancy during the
study. Among the 117 women who became pregnant dur-
ing the study period, the incidence rate of HSV-2 serocon-
version was 10.1 (4.9 – 18.5) cases per 100 person-years.
The temporal relationship between HSV-2 infection andBMC Infectious Diseases 2007, 7:113 http://www.biomedcentral.com/1471-2334/7/113
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date of conception was not defined by our data. HSV-2
incidence by African American race and unintended preg-
nancy during the study is presented in Figure 1.
In the bivariate analysis several factors, all assessed at
enrolment, were significantly associated with an increased
risk of incident HSV-2 infection including African Ameri-
can race (OR 2.14 [1.10–4.16]), history of pregnancy (OR
1.80 [1.12–2.89]), CT infection at enrolment (OR 2.62
[1.15–5.95]), multiple sex partners within the last six
months (OR 1.63 [1.01–2.65]), last sexual intercourse
was unprotected (OR 2.27 [1.22–4.25]), last partner over
Table 1: HSV-2 seropositivity by select demographic and behavioural factors at baseline
Risk Factors Total (%) HSV-2 seropositivity P value
n%
Total 2104 (100) 170 8.1
Race
White 647 (30.8) 42 6.5 <0.0001
Latina 419 (19.9) 43 10.3
Black 312 (14.8) 42 13.5
API 467 (22.2) 20 4.3
Multi/Other 259 (12.3) 23 8.9
Age
15–19 959 (45.6) 52 5.4 <0.0001
20–24 1145 (54.4) 118 10.3
Age at first sexual intercourse
>15 years 1214 (57.7) 84 6.9 0.023
≤ 15 years 890 (42.3) 86 9.7
Ever pregnant
No 1425 (67.7) 90 6.3 < 0.0001
Yes 679 (32.3) 80 11.8
Ever diagnosed with an STI (N = 2101)
No 1621 (78.5) 102 6.3 < 0.0001
Yes 445 (21.5) 68 15.3
Number of partners in last 6 months
1 partner 1514 (72.0) 114 7.5 0.138
≥ 2 partners 590 (28.0) 56 9.5
Reason for visit
OCPs 516 (24.5) 41 8.0 0.100
Pregnancy Test 125 (5.9) 8 6.4
STI/HIV Test 250 (11.9) 31 12.4
Annual/Pap 496 (23.6) 40 8.1
Othera 710 (33.7) 50 6.8
HSV-2, herpes simplex virus type 2; API, Asian or Pacific Islander; OCP, oral contraceptive pill; STI, sexually transmitted infection; HIV, Human 
Immunodeficiency Virus; Pap, Papinikolaou smear.
a Other reasons for visit included: colposcopy, miscellaneous reproductive health needs, other health complaints, no reason given, or no 
appointment at enrolment.BMC Infectious Diseases 2007, 7:113 http://www.biomedcentral.com/1471-2334/7/113
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25 years old (OR 1.70 [1.04–2.77]), and pressured into
sex in last six months (OR 2.21 [1.03–4.76]). Condom
use at last intercourse was found to be protective (OR 0.62
[0.39–1.00]). After adjusting for confounders in multivar-
iable regression analysis, however, only African American
race (OR 2.31 [1.28–4.14]), multiple sex partners within
the last six months (OR 1.75  [1.07–2.89]) and the protec-
tive effect of condom use at last intercourse remained sig-
nificant (OR 0.56 [0.34–0.92]). These results are
summarized in Table 2.
Discussion
HSV-2 seroincidence and the unintended pregnancy rate
in young women receiving family planning services in San
Francisco clinics over a 6-month period were high at 7.8
and 12.7 per 100 person-years, respectively. The rate of
HSV-2 acquisition in women who became pregnant dur-
ing the study period was 10.1 cases per 100 person-years.
Seroincidence of HSV-2 has recently been reported as 7.3
cases per 100 person-years in a study of 100 sexually active
females aged 14 to 17 years [12]. A larger study found a
HSV-2 seroincidence of 13.2 cases per 100 person-years in
males and females aged 14 to 24 at inner city STD clinics
in the mid 1990's [13]. Our own data, along with these,
are consistent with the increase in HSV-2 seroprevalence
observed nationally as women move from adolescence
into their late twenties [7]. We are unaware of other stud-
ies demonstrating high rates of unintended pregnancy in
a population of young women that also has high seroinci-
dent HSV-2.
Recent NHANES data showed higher HSV-2 seropreva-
lence associated with increasing age, younger age at first
intercourse, number of lifetime sexual partners, and pov-
erty [7]. African American women also had relatively high
HSV-2 seropositivity [7]. While bivariate analysis of our
data suggested several baseline behavioural and demo-
graphic predictors of HSV-2 seroincidence, multivariable
analysis found African American race and multiple sex
partners within the last six months increased the likeli-
hood of new infection. The risks were high: African Amer-
ican women were nearly 2.5 times more likely to acquire
HSV-2 infection than non-African American women and
those with multiple partners were 75% more likely. Clini-
cians should be aware of the significant increased risk
associated with these factors.
Our findings showed condom use at the last intercourse
prior to enrolment was highly protective, associated with
a 44% reduction in likelihood for acquiring HSV-2 after
adjustment for confounders. This is consistent with a
recent study by Wald et al showing that STD clinic patients
reduced their risk for HSV-2 by 26% as they increased con-
dom use frequency [14]. Our study is at least the fourth to
demonstrate that condom use was associated with
decreased HSV acquisition and should encourage medical
providers and policy makers to feel confident in recom-
mending condom use to decrease HSV-2 transmission
[13-15].
We observed a high rate of unintended pregnancies in an
urban, racially diverse group of young women. This con-
curs with findings from the National Survey of Family
Growth for 2001 that showed poor, uneducated, minority
women are at increased risk for unintended pregnancy [9].
Interestingly, nearly half of these unintended pregnancies
occurred in women reporting concurrent contraceptive
use [9]. While participants did not intend to become preg-
nant in the next six months at enrolment, they could have
changed their minds after enrolment and intentionally
conceived before the 6-month follow up appointment.
Information regarding change in intention in the interim
was not collected.
The role of HSV in the development of severe neonatal
complications following maternal infection is well known
[3-5]. Brown et al recently reported a neonatal herpes
infection rate of 1 in 3200 live births (31.25 per 100,000
live births) for several hospitals around Seattle, Washing-
ton [6]. Others have reported incidences of 11 to 33 infec-
tions per 100,000 live births [16-18]. Rates of neonatal
herpes are highest in neonates born to recently HSV-
infected women who were seronegative pre-pregnancy
[6]. Our data suggest that young women in San Francisco
run a high risk of acquiring HSV-2 infection shortly before
and during their pregnancies.
Herpes simplex virus type 2 (HSV-2) seroincidence in  women from San Francisco aged 15 to 24 years by African  American race and new pregnancy during the 6-month study  period Figure 1
Herpes simplex virus type 2 (HSV-2) seroincidence in 
women from San Francisco aged 15 to 24 years by African 
American race and new pregnancy during the 6-month study 
period. Seroincidence expressed as cases per 100 person 
years. N = 1672.
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Table 2: HSV-2 seroconversion by selected demographic and behavioural factors
HSV-2 seroconversion COR (95% CI) AOR (95% CI)
%n / N
Total 4.4 73/1672
Race
White 3.7 19/519 Referent
Latina 3.7 12/322 1.02 (0.49–2.13)
Black 7.5 18/239 2.14 (1.10–4.16) 2.31 (1.28–4.14)
API 3.6 14/389 0.98 (0.49–1.99)
Multi/Other 4.9 10/203 1.36 (0.62–2.99)
Age
15–19 3.6 29/801 Referent
20–24 5.1 44/871 1.42 (0.88–2.29) 0.89 (0.50–1.58)
Age at first sexual intercourse
> 15 years 4.7 45/960 Referent
≤ 15 years 3.9 28/712 0.83 (0.51–1.35)
Ever pregnant
No 3.6 41/1156 Referent
Yes 6.2 32/516 1.80 (1.12–2.89) 1.61 (0.99–2.63)
Ever diagnosed with an STI (N = 1640)
No 4.0 53/1312 Referent
Yes 6.1 20/328 1.54 (0.91–2.62)
CT-infected at enrollment (N = 1640)
No 4.2 66/1572 Referent
Yes 10.3 7/68 2.62 (1.15–5.95)
Number of partners in last 6 months
1 partner 3.7 45/1203 Referent
≥ 2 partners 6.0 28/469 1.63 (1.01–2.65) 1.75 (1.07–2.89)
Any unprotected sexual intercourse in last 6 months (N = 1670)
No 3.6 32/900 Referent
Yes 5.3 41/770 1.53 (0.95–2.45)
Last sexual intercourse was unprotected (N = 1671)
No 4.0 60/1519 Referent
Yes 8.6 13/152 2.27 (1.22–4.25)
Currently uses condoms (N = 1671)
No 4.9 29/592 Referent
Yes 4.1 44/1079 0.83 (0.51–1.33)BMC Infectious Diseases 2007, 7:113 http://www.biomedcentral.com/1471-2334/7/113
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These findings highlight the need for multiple interven-
tions to minimize acquisition of HSV-2 infection in the
young urban female population. Possible effective inter-
ventions include targeted screening and vaccination
among women seeking family planning services as these
women are at high risk for unintended pregnancy, despite
contraceptive use. Targeted screening could include
women who are African American or who report multiple
sex partners within the last six months. We think it is also
important for providers who counsel women on contra-
ceptive services and STI prevention to play an expanded
role in counselling women about prevention of HSV-2
infection given the potential sequelae in pregnancy. While
vaccine development requires extensive bench to bedside
translational research, the other interventions listed are
well within the grasp of existing public health institutions
and future studies should evaluate their effectiveness in
reducing the burden of new HSV-2 infections in young
women at risk for unintended pregnancy.
Also pertinent to this discussion, it has been suggested
that HSV-2 antibody screening may place unnecessary
psychological stress on individuals, as there is typically no
intervention indicated for asymptomatic cases [19,20].
Ample research by our group and others, however, indi-
cates that HSV-2 testing does not cause inappropriate lev-
els of psychological distress and thus prevention strategies
that incorporate routine HSV-2 testing may be warranted
[21-24]. At the least, the evaluation of such strategies
should be a public health priority.
With regard to limitations, the main study, of which this
is a sub-study, was designed to examine emergency con-
traception on reproductive health outcomes in women
using high compliance contraceptives not intending to
become pregnant in the next six months. These criteria
resulted in the exclusion of half of the women initially
screened. Women using methods requiring a lower degree
of user compliance, including injectable contraception
and IUDs, would be expected to have a lower unintended
pregnancy rate. Because women using low compliance
methods were excluded, the unintended pregnancy rate
calculated in our study may be an overestimate of the
actual rate. However, these women tend to use condoms
less frequently and, as a result, their exclusion may have
led to an underestimation of HSV-2 seroincidence in our
study. A cohort assembled with incident HSV-2 infection
and pregnancy as the sole primary research endpoints
might have avoided these potential biases.
Fourteen percent of women did not complete HSV-2 test-
ing at 6-month follow-up. While the majority (64%) of
these women were lost to follow-up, those remaining
completed telephone interviews at follow-up for the main
study but were not available for repeat fingerstick blood
testing for HSV-2 or pregnancy testing. It is unknown how
this impacted the measures of incidence or of associa-
tions. An analysis of attrition for the main study showed
no significant differences in baseline demographic traits,
history of pregnancy or STIs, or contraceptive methods
between those who completed the study and those lost to
follow-up.
In addition, we relied on the self-report of sexual risk
behaviours, which women may recall with varying
degrees of accuracy. This is a limitation of our study and,
indeed, of other studies seeking to characterize behav-
ioural factors affecting the acquisition of sexually trans-
mitted infections. By contrast, the use of both urine
testing, self-report and medical chart review in our assess-
ment of new pregnancies is a strength of our study,
although it is possible that some women may have under-
reported new pregnancies during the study period that
were terminated before urine testing at follow-up.
Condom use at last intercourse (N = 1671)
No 5.5 40/728 Referent
Yes 3.5 33/943 0.62 (0.39–1.00) 0.56 (0.34–0.92)
Pressured into having sex in last 6 months (N = 1667)
No 4.1 65/1575 Referent
Yes 8.7 8/92 2.21 (1.03–4.76)
Last sexual partner over 25 years old (N = 1672)
No 3.7 46/1235 Referent
Yes 6.2 27/437 1.70 (1.04–2.77) 1.58 (0.90–2.76)
HSV-2, herpes simplex virus type 2; COR, crude odds ratio; AOR, adjusted odds ratio; CI, confidence interval; API, Asian or Pacific Islander; STI, 
sexually transmitted infection; CT, Chlamydia trachomatis.
Table 2: HSV-2 seroconversion by selected demographic and behavioural factors (Continued)BMC Infectious Diseases 2007, 7:113 http://www.biomedcentral.com/1471-2334/7/113
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Finally, although the rapid point-of-care test we used to
identify HSV-2 infection has a documented high sensitiv-
ity (96%) and specificity (98%), it is not as accurate as
Western blot. A few women may have been falsely identi-
fied as HSV-2 positive while others may have been falsely
identified as HSV-2 negative, especially if they had low
HSV-2 titre levels. This would result in non-directional
misclassification and would bias our findings towards not
finding significant predictors of HSV-2 infection. There-
fore our findings may have been stronger if we had used a
more accurate test.
Conclusion
To conclude, our prospective cohort study of young, sexu-
ally active women characterized the epidemiology of inci-
dent HSV-2 infection in this important population. The
inclusion of incident pregnancy data demonstrates the
considerable ongoing threat of new HSV-2 infection in
women who are pregnant or at risk of unintended preg-
nancy. Clinicians need to have a clear idea of the risk of
exposure to HSV-2 in young women who have a high like-
lihood of becoming pregnant regardless of pregnancy
intentions. Specific HSV-2 education should be routinely
offered to women obtaining family planning services.
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